"Cholesterol, HDL" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Cholesterol which is contained in or bound to high-density lipoproteins (HDL), including CHOLESTEROL ESTERS and free cholesterol.
| Descriptor ID |
D008076
|
| MeSH Number(s) |
D04.210.500.247.808.197.238 D10.532.432.400 D10.570.938.208.270 D12.776.521.479.470
|
| Concept/Terms |
Cholesterol, HDL- Cholesterol, HDL
- alpha-Lipoprotein Cholesterol
- Cholesterol, alpha-Lipoprotein
- alpha Lipoprotein Cholesterol
- HDL Cholesterol
- High Density Lipoprotein Cholesterol
|
Below are MeSH descriptors whose meaning is more general than "Cholesterol, HDL".
Below are MeSH descriptors whose meaning is more specific than "Cholesterol, HDL".
This graph shows the total number of publications written about "Cholesterol, HDL" by people in this website by year, and whether "Cholesterol, HDL" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 3 | 3 |
| 1997 | 0 | 2 | 2 |
| 1998 | 2 | 2 | 4 |
| 1999 | 0 | 1 | 1 |
| 2000 | 1 | 7 | 8 |
| 2001 | 1 | 9 | 10 |
| 2002 | 0 | 5 | 5 |
| 2003 | 4 | 5 | 9 |
| 2004 | 0 | 5 | 5 |
| 2005 | 3 | 5 | 8 |
| 2006 | 2 | 0 | 2 |
| 2007 | 2 | 4 | 6 |
| 2008 | 4 | 11 | 15 |
| 2009 | 4 | 3 | 7 |
| 2010 | 2 | 4 | 6 |
| 2011 | 2 | 5 | 7 |
| 2012 | 2 | 6 | 8 |
| 2013 | 2 | 2 | 4 |
| 2014 | 0 | 4 | 4 |
| 2015 | 2 | 2 | 4 |
| 2016 | 1 | 1 | 2 |
| 2017 | 1 | 3 | 4 |
| 2018 | 1 | 2 | 3 |
| 2019 | 1 | 4 | 5 |
| 2020 | 1 | 0 | 1 |
| 2021 | 1 | 3 | 4 |
| 2022 | 0 | 2 | 2 |
| 2023 | 0 | 2 | 2 |
| 2024 | 0 | 3 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Cholesterol, HDL" by people in Profiles.
-
Lower activity of cholesteryl ester transfer protein (CETP) and the risk of dementia: a Mendelian randomization analysis. Alzheimers Res Ther. 2024 Oct 16; 16(1):228.
-
Guiding Dyslipidemia Treatment: A Population Pharmacokinetic-Pharmacodynamic Framework for Obicetrapib. J Clin Pharmacol. 2024 Sep; 64(9):1150-1164.
-
Obicetrapib on top of maximally tolerated lipid-modifying therapies in participants with or at high risk for atherosclerotic cardiovascular disease: rationale and designs of BROADWAY and BROOKLYN. Am Heart J. 2024 08; 274:32-45.
-
Obicetrapib: Reversing the Tide of CETP Inhibitor Disappointments. Curr Atheroscler Rep. 2024 02; 26(2):35-44.
-
The relationship between high density lipoprotein cholesterol and sepsis: A clinical and genetic approach. Clin Transl Sci. 2023 03; 16(3):489-501.
-
Cholesteryl Ester Transfer Protein Inhibition Reduces Major Adverse Cardiovascular Events by Lowering Apolipoprotein B Levels. Int J Mol Sci. 2022 Aug 20; 23(16).
-
Sex differences in the association of vital exhaustion with regional fat deposition and subclinical cardiovascular disease risk. J Psychosom Res. 2022 06; 157:110785.
-
Lipid Levels and Short-Term Risk of Recurrent Brain Infarcts in Symptomatic Intracranial Stenosis. J Stroke Cerebrovasc Dis. 2022 Jan; 31(1):106141.
-
Lipid measurements in the management of cardiovascular diseases: Practical recommendations a scientific statement from the national lipid association writing group. J Clin Lipidol. 2021 Sep-Oct; 15(5):629-648.
-
Blocking endothelial lipase with monoclonal antibody MEDI5884 durably increases high density lipoprotein in nonhuman primates and in a phase 1 trial. Sci Transl Med. 2021 04 21; 13(590).